Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: Signal refinement using active safety surveillance

Therapeutic Advances in Drug Safety

Volumn 3, Issue 4, 2012, Pages 157-164

  Dore, David D ^a   Seeger, John D ^b,c,d   Chan, K Arnold ^b,d  

^a BROWN UNIVERSITY   (United States)

^b OPTUM   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

active safety surveillance; exenatide; pancreatic cancer; safety signal; thyroid cancer

Indexed keywords

EXENDIN 4; GLIBENCLAMIDE; METFORMIN;

ADULT; ARTICLE; CORRELATION ANALYSIS; DRUG INDUCED CANCER; DRUG SURVEILLANCE PROGRAM; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS TUMOR; PRIORITY JOURNAL; PROPENSITY SCORE; RISK ASSESSMENT; THYROID TUMOR;

EID: 84868633590     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098612446473     Document Type: Article

References (19)

1. Altekruse S.F. Kosary C.L. Krapcho M. Neyman N. Aminou R. Waldron W. (eds) (2010) Seer Cancer Statistics Review, 1975–2007. Bethesda, MD: National Cancer Institute. Based on November 2009 Seer Data Submission, posted to the Seer Web Site. Available at: http://seer.cancer.gov/csr/1975_2007/ (accessed 10 April 2012).
2. Committee on the Assessment of the US Drug Safety System (2007) The Future of Drug Safety: Promoting and Protecting the Health of the Public. Baciu A. Stratton K.R. Burke S.P. (eds). Washington, DC: National Academies Press.
3. Crystal S. Akincigil A. Bilder S. Walkup J.T. (2007) Studying prescription drug use and outcomes with Medicaid claims data: strengths, limitations, and strategies. Med Care 45: S58–S65.
4. Currie C.J. Poole C.D. Gale E.A. (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766–1777.
5. Dore D.D. Bloomgren G.L. Wenten M. Hoffman C. Clifford C.R. Quinn S.G. (2011) A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 13: 559–566.
6. Dore D.D. Seeger J.D. Chan K.A. (2009) Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 25: 1019–1027.
7. Elashoff M. Matveyenko A.V. Gier B. Elashoff R. Butler P.C. (2011) Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies. Gastroenterology 141: 150–156.
8. International Conference on Harmonisation (ICH) (1995). Guideline for Industry: The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions. ICH-E1A. Federal Register. March 1, 1995 (60 FR 11270).
9. Jurek A.M. Greenland S. Maldonado G. (2008) How far from non-differential does exposure or disease misclassification have to be to bias measures of association away from the null? Int J Epidemiol 37: 382–385.
10. Lanes S.F. de Luise C. (2006) Bias due to false-positive diagnoses in an automated health insurance claims database. Drug Saf 29: 1069–1075.
11. Leister K.A. Edwards W.A. Christensen D.B. Clark H. (1981) A comparison of patient drug regimens as viewed by the physician, pharmacist and patient. Med Care 19: 658–664.
12. McKenzie D.A. Semradek J. McFarland B.H. Mullooly J.P. McCamant L.E. (2000) The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 53: 1248–1257.
13. Parks M. Rosebraugh C. (2010) Weighing risks and benefits of liraglutide – the FDA–s review of a new antidiabetic therapy. N Engl J Med 362: 774–777.
14. Rosenbaum P.R. Rubin D.B. (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70: 41–55.
15. Seeger J.D. Williams P.L. Walker A.M. (2005) An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 14: 465–476.
16. Setoguchi S. Solomon D. Glynn R. Cook E. Levin R. Schneeweiss S. (2007) Agreement of diagnosis and its date for hematologic malignancies and solid tumors between Medicare claims and cancer registry data. Cancer Causes and Control 18: 561–569.
17. VICTOZA Prescribing Information. Available from: http://www.victoza.com/pdf/PI_(1_Column_Format).pdf. (accessed 10 February 2010).
18. Walker A.M. (2001) Pattern recognition in health insurance claims databases. Pharmacoepidemiol Drug Saf 10: 393–397.
19. West S.L. Savitz D.A. Koch G. Strom B.L. Guess H.A. Hartzema A. (1995) Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142: 1103–1112.